LncRNA SNHG6 role in clinicopathological parameters in cancers

Khan, Khushbukhat; Irfan, Muhammad; Sattar, Areej Abdul; Faiz, Manal Bint; Rahman, Anees ur; Athar, Hafsa; Calina, Daniela; Sharifi-Rad, Javad; Cho, William C.

doi:10.1186/s40001-023-01358-2

European Journal of Medical Research

Table 2 Summary of research findings on the role of SNHG6 in various cancers

From: LncRNA SNHG6 role in clinicopathological parameters in cancers

Cancer type	Function of SNHG6	Mechanism of action	Effect on cellular processes	Involved miRNAs	Affected genes and enzymes	References
Tongue and esophageal cancers	Promotes EMT, proliferation, and drug resistance	Down-regulates miR-186-5p, promotes HIF1α, interacts with EZH2	Increased metastasis, reduced apoptosis	miR-186-5p	HIF1α, EZH2, Bcl-2, MCL-1, Bax, caspase-3	[105, 130,131,132,133,134]
Gastric cancer	Inhibits apoptosis, promotes cell growth	Sequesters miR-101-3p, regulates EZH2	Increased metastasis, reduced apoptosis	miR-101-3p	EZH2, p21, ZEB1	[33, 81, 111, 135, 136]
Liver cancer (HCC)	Promotes tumor growth and metastasis	Interacts with UPF1, inhibits let-7c-5p, sponges miR-139-5p	Increased cell proliferation, reduced apoptosis	let-7c-5p, miR-139-5p	c-Myc, SERPINH1, TAK1, SETD7, LZTFL1	[31, 85, 138,139,140, 142, 143]
Pancreatic cancer	Counters drug resistance	Neutralizes miR-944	Improved drug sensitivity	miR-944	KPNA5	[144]
Colorectal cancer (CRC)	Promotes cell growth and metastasis	Regulates EZH2, inhibits p21, modulates miR-26a/b, miR-214	Increased metastasis, reduced apoptosis	miR-26a/b, miR-214	EZH2, E2F, p21, PKM, hnRNPA1	[38, 72, 79, 88, 102, 145, 146]
Tongue and esophageal cancers	Promotes EMT, proliferation, and drug resistance	Down-regulates miR-186-5p, promotes HIF1α, interacts with EZH2	Increased metastasis, reduced apoptosis	miR-186-5p	HIF1α, EZH2, Bcl-2, MCL-1, Bax, caspase-3	[105, 130, 132,133,134]
Gastric cancer	Inhibits apoptosis, promotes cell growth	Sequesters miR-101-3p, regulates EZH2	Increased metastasis, reduced apoptosis	miR-101-3p	EZH2, p21, ZEB1	[33, 81, 111, 135, 136]
Liver cancer	Promotes tumor growth and metastasis	Interacts with UPF1, inhibits let-7c-5p, sponges miR-139-5p	Increased cell proliferation, reduced apoptosis	let-7c-5p, miR-139-5p	c-Myc, SERPINH1, TAK1, SETD7, LZTFL1	[31, 85, 138,139,140, 142, 143]
Pancreatic cancer	Counters drug resistance	Neutralizes miR-944	Improved drug sensitivity	miR-944	KPNA5	[144]
Colorectal cancer	Promotes cell growth and metastasis	Regulates EZH2, inhibits p21, modulates miR-26a/b, miR-214	Increased metastasis, reduced apoptosis	miR-26a/b, miR-214	EZH2, E2F, p21, PKM, hnRNPA1	[38, 72, 79, 88, 102, 145, 146]
Bladder and kidney cancer	Oncogenic	Increases Snail1/2 for EMT; sequesters miR-125b	Increases cell proliferation, migration, invasion; induces apoptosis on knockdown	miR-125b, miR-15a	Snail1/2, NUAK1, p53, cyclin D	[98, 151]
Prostate cancer	Oncogenic; prognostic marker	Not fully elucidated; affects miR-186	Increases cell proliferation, invasion, migration; enhances PTX resistance	miR-186	Not fully elucidated	[34, 152]
Ovarian cancer	Oncogenic	Sponges miR-4465 and miR-543; regulates EZH2 and YAP1	Increases intravasation, metastasis, proliferation; induces EMT	miR-4465 miR-543	EZH2, YAP1	[153, 154]
Bone cancer	Oncogenic	Sponges miR-26a-5p; modulates KLF2, p21, ULK-1	Induces cell cycle arrest at G0/G1, growth inhibition, attenuates invasion; modulates autophagy and apoptosis	miR-26a-5p	KLF2, p21, ULK-1	[62, 89, 155]

EMT: epithelial–mesenchymal transition; miR-186-5p, miR-101-3p, let-7c-5p, miR-139-5p, miR-26a/b, miR-214, miR-125b, miR-15a, miR-4465, miR-543, miR-944: Types of microRNAs (miRNAs); HIF1α: hypoxia-inducible factor 1 alpha; EZH2: enhancer of zeste homolog; Bcl-2: B cell lymphoma 2; MCL-1: myeloid cell leukemia 1; Bax: Bcl-2-associated X protein; caspase-3: cysteine-dependent aspartate-directed protease 3; p21: cyclin-dependent kinase inhibitor 1A; ZEB1: zinc finger E-box binding homeobox 1; UPF1: up-frameshift suppressor 1; c-Myc: cellular myelocytomatosis viral oncogene; SERPINH1: serpin family H member 1; TAK1: transforming growth factor beta-activated kinase 1; SETD7: SET domain containing lysine methyltransferase 7; LZTFL1: leucine zipper transcription factor-Like 1; KPNA5: karyopherin subunit alpha 5; E2F: E2F transcription factors; PKM: pyruvate kinase M; hnRNPA1: heterogeneous nuclear ribonucleoprotein A1; Snail1/2: snail family transcriptional repressors 1 and 2; NUAK1: NUAK family kinase 1; p53: tumor protein p53; cyclin D: cyclin D protein family; PTX: paclitaxel; KLF2: Krüppel-like factor 2; ULK-1: unc-51 like autophagy activating kinase 1; YAP1: yes-associated protein 1; G0/G1: phases of the cell cycle

Back to article page

ISSN: 2047-783X

Contact us

Submission enquiries: jacinth.kennady@springernature.com
General enquiries: info@biomedcentral.com